Immune-Onc, an immuno-oncology therapy developer exploiting University of Texas research, has received more than $33m from investors including Stanford-StartX fund.
Immune-Onc, a US-based immuno-oncology therapy developer partly based on University of Texas research, has received more than $33m in series B funding from investors including Stanford-StartX fund.
VC firm Northern Light Venture Capital and healthcare-focused investment firm Vivo Capital both participated in the series B round.
Founded in 2015, Immune-Onc is developing immunotherapies for cancer that focus on infiltrating tumours and unwinding the suppression of the patient’s immune system.
The company’s lead program, IO-202, will primarily target acute myeloid leukaemia, a blood-borne cancer originating in bone marrow, in addition to other haematological and solid tumours. IO-202 is currently in pre-clinical studies.
Immune-Onc gained exclusive commercialisation rights for biotherapeutics in April 2017 from two University of Texas system institutions, University of Texas Health Science Center at Houston and University of Texas Southwestern Medical Center.
The business previously attracted $7m in a 2016 series A round backed…
